Trial Profile
Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose IL-2 in Patients With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Pembrolizumab (Primary) ; Tumour infiltrating lymphocytes (Primary)
- Indications Malignant melanoma; Skin cancer; Uveal melanoma
- Focus Therapeutic Use
- 27 Oct 2022 Status changed from active, no longer recruiting to completed.
- 29 Jun 2022 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.
- 29 Jun 2022 Planned primary completion date changed from 31 Aug 2022 to 31 Aug 2023.